New Data from Past BACE Inhibitor Trials Shed Light on Side Effects
16 Dec 2020 BACE inhibitors succeeded in stemming the tide of Aβ production in the brain, but the drugs also slightly dulled cognition and shrank the brain, bringing the trials to a screeching halt. Rather than washing their hands of a failure and moving on, researchers continue to dig through the trial data to find out exactly what happened, and perhaps even to chart a way forward for the drugs. Three recent studies—all led by Michael Egan at Merck—add new insight. Verubecestat triggered a rapid atrophy that did not get worse. This happened in amyloid-rich regions, and did not track wit...
Source: alzforum.org